- Cash and investments ended at approximately $315 million, above plan, supporting the path to positive cash flow by end of 2027.
- Instrument revenue was $14.2 million, down 4% year-over-year due to funding constraints in academic and government customers, while consumables revenue grew 11% to $18.9 million.
- Non-GAAP gross margin improved to 38.3%, driven by favorable product mix and lower Revio consumable unit costs.
- Non-GAAP net loss narrowed to $40.0 million ($0.13 per share) from $55.2 million ($0.20 per share) in Q2 2024.
- Non-GAAP operating expenses decreased 18% year-over-year to $58.1 million, reflecting restructuring and lower stock-based compensation.
- PacBio reported Q2 2025 revenue of $39.8 million, up 7% sequentially and 10% year-over-year, driven by strong international growth with APAC and EMEA regions up 45% combined.
Related items and other data are not available for this feed item.
Dafinchi